WALL STREET TRADER
SPECIAL SITUATION
CURE PHARMA HOLDG CORP
CURR OTCQB
These shares have bottomed recently and begun to reverse bouncing from an oversold condition . It could be time to consider this company and place CURR on your WATCH LIST
With a yearly high of $1.22 and first upside resistance at $0.50 cents and we feel this stock merits your attention ..This company has a convertible note outstanding for $6.9 million which has depressed its shares. A recent forbearance agreement with the lender has relieved the downside pressure and the shares may again begin to reflect its true value .
Serious investors must place these shares on their WATCH LIST
CURE Pharmaceutical and Milagro Pharmaceuticals Collaborate for Registration and Approval to Sell Sildenafil Oral Thin Film in Mexico
COFEPRIS (Mexico’s equivalent of the US FDA) grants authorization for the manufacture, distribution and sale in Mexico of CURE’s Sildenafil, Vitamin D3, Electrolyte, Energy, and Sleep products in CURE’s patented Oral Thin Film (OTF) dose form CUREform™
OXNARD, Calif. and LAS VEGAS, March 03, 2022 (GLOBE NEWSWIRE) — Cure Pharmaceutical (OTC: CURR) a developer and manufacturer of innovative delivery formulations for drugs, supplements and wellness products, and Milagro Pharmaceuticals, which seeks first mover advantage in target heath & wellness markets through key collaborations, today announced their collaboration to register and sell in Mexico a number of CURE’s OTC and medical compounds that utilize CUREform™, CURE’s patented drug delivery platform for oral thin film (OTF). Cure is in discussions with several large distributors in Mexico and Latin America.
OTF products that will be marketed and sold in Mexico via key distribution partners, include:
- CUREfilm Blue™ – an oral soluble form of sildenafil citrate (the active ingredient present in Viagra ®1 ) for the treatment of erectile dysfunction (ED).
- Vitamin D3 – that provides a convenient, weekly 40,000 IU dose of Vitamin D
- An electrolyte energy boost – that provides a healthier, sugar-free alternative to energy drinks
- Sleep – a dose of melatonin that dissolves on the tongue so it can be taken even after you climb into bed.
The opportunity to serve the Latin American market with this venture into Mexico is an exciting one that is expected to accelerate the ramp up of CURE’s FDA-registered, cGMP manufacturing facility, where the Company pioneered and developed its patented CUREfilm™, drug delivery platform. The Company expects to select a distribution partner for the the LATAM territory in the coming months.
Martin Simon, CEO of Milagro Pharmaceuticals, stated, “We are pleased to be working with CURE to bring their innovative wellness products and proprietary drug forms and delivery systems to Mexico, with the intention to extend our collaboration to encompass the rest of Latin America where the demand for health & wellness products is growing more rapidly than many other parts of the world.”
About CURE Pharmaceutical
CURE is the pioneering developer of CUREform™, a patented drug delivery platform that offers a number of unique immediate- and controlled-release drug delivery vehicles designed to improve drug efficacy, safety, and patient experience for a wide range of active ingredients.
As a vertically integrated company, CURE’s 25,000 square foot, FDA and DEA registered, NSF ® cGMP-certified manufacturing facility enables it to partner with pharmaceutical and wellness companies worldwide for private and white-labeled production.
About Milagro Pharmaceuticals
Milagro Pharmaceuticals is dedicated to the innovation, distribution, and sale of various disruptive technologies all focused on healing people. The company’s growth has driven its recent expansion into Colombia, Canada and now Mexico.
About COFEPRIS
COFEPRIS (the Federal Commission for Protection against Sanitary Risk (Comisión Federal para la Protección contra Riesgos Sanitarios) is the Mexican authority responsible for enforcing the regulatory framework relating to medical products and is part of the Ministry of Health (Secretaria de Salud).
Forward Looking Statement
Statements CURE makes in this press release may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”), which are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. CURE intends these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act and is making this statement for purposes of complying with those safe harbor provisions. The forward-looking statements in this press release reflect CURE’s judgment as of the date of this press release. CURE disclaims any intent or obligation to update these forward-looking statements.
1 Viagra ® is a registered trademark of Pfizer Inc.
Investor Contact:
Website: www.plumtreeconsultingllc.com
Neither PSN nor its owners, members, officers, directors, partners, consultants, nor anyone involved in the publication of this website, is a registered investment adviser or broker-dealer or associated person with a registered investment adviser or broker-dealer and none of the foregoing make any recommendation that the purchase or sale of securities of any company profiled in the PSN website is suitable or advisable for any person or that an investment or transaction in such securities will be profitable. The information contained in the PSN website is not intended to be, and shall not constitute, an offer to sell nor the solicitation of any offer to buy any security. The information presented in the PSN website is provided for informational purposes only and is not to be treated as advice or a recommendation to make any specific investment. Please consult with an independent investment adviser and qualified investment professional before making an investment decision.d. Writer is paid $800